1
                                                                      EXHIBIT 17

                                                                         N E W S
                                                           FOR IMMEDIATE RELEASE

[BOSTON SCIENTIFIC LOGO]

                                                   Boston Scientific Corporation
                                                   One Boston Scientific Place
                                                   Natick, MA 01760-1637

                                                   508.650.8000

                                                   www.bsci.com


                BOSTON SCIENTIFIC AND CARDIAC PATHWAYS ANNOUNCE
              WAITING PERIOD PURSUANT TO HART-SCOTT-RODINO ACT HAS
                                    EXPIRED

Natick, MA and Sunnyvale, CA (July 31, 2001) -- Boston Scientific Corporation
(NYSE: BSX) and Cardiac Pathways Corporation (NASDAQ: CPWY) announced today that
the waiting period with respect to Boston Scientific's offer to purchase all the
outstanding shares of Cardiac Pathways common stock, par value $0.001 per share,
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has
expired. Accordingly, all applicable domestic and foreign antitrust obligations
have been complied with, and the condition to the offer to purchase requiring
the expiration or termination of the waiting period under the Act has been
satisfied.

The companies announced on June 29 the signing of a definitive agreement for
Boston Scientific to acquire Cardiac Pathways in an all cash transaction for a
purchase price of approximately $115 million.

The tender offer is scheduled to expire at 12:00 midnight, New York City Time,
on Monday, August 6, 2001, unless the offer is extended.

The offer for all the outstanding shares of Cardiac Pathways common stock is
being made through, and the foregoing announcement is qualified in its entirety
by reference to, Adam Acquisition 2001 Inc.'s Tender Offer Statement on Schedule
TO, including the Offer to Purchase dated July 10, 2001, and the related letter
of transmittal, which can be obtained for free, along with other filed
documents, at the SEC's website www.sec.gov. Cardiac Pathways stockholders
should read the Offer to Purchase and related letter of transmittal in their
entirety before making any decision as to whether to tender their shares into
the offer.

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices. The company's products are used in a broad range of
interventional medical specialties.

                                   -- more --

   2
Boston Scientific Corporation/Page 2
July 31, 2001


Cardiac Pathways designs, manufactures and markets minimally invasive systems
used by electrophysiologists to diagnose and treat cardiac tachyarrhythmias
(abnormally rapid heart rhythms), which if untreated can cause palpitations,
fainting and sudden cardiac arrest. Cardiac Pathways' products consist
principally of systems for performing ablation treatment (a nonsurgical,
minimally invasive technique for neutralizing heart tissue responsible for
starting or maintaining a tachyarrhythmia) and for diagnostic mapping (locating
the source of the tachyarrhythmia within the heart).

                    CONTACT:  Milan Kofol (508-650-8569)
                              Investor Relations
                              Boston Scientific Corporation

                              Paul Donovan (508-650-8541)
                              Media Relations
                              Boston Scientific Corporation

                              Eldon Bullington (408-720-2864)
                              Vice President Finance and Chief Financial Officer
                              Cardiac Pathways Corporation